Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
24/12/2025 12:08
Dec 24 (Reuters) - Repare Therapeutics Inc RPTX.O: REPARE THERAPEUTICS ANNOUNCES ACQUISITION OF POLΘ ATPASE INHIBITOR, RP-3467, BY GILEAD SCIENCES FOR UP TO $30 MILLION IN TOTAL CONSIDERATION REPARE THERAPEUTICS INC - GILEAD TO BUY RP-3467 FROM REPARE FOR UP TO $30 MILLION REPARE THERAPEUTICS INC - TO RECEIVE $25 MILLION UPFRONT, $5 MILLION ON TECH TRANSFER Source text: ID:nBw2zwPCla Further company coverage: RPTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln